S1 Fig -
journal contribution
posted on 2025-01-24, 18:51 authored by Rodrigo Papa-Gobbi, Pablo Stringa, Maria Virginia Gentilini, Ivana Ivanoff, Mariana Machuca, Nidia Monserrat Arreola, Javier Serradilla, Karla Estefanía-Fernández, Paloma Talayero, María Velayos, Elena Sánchez—Zapardiel, Gabriel Gondolesi, Ane Andrés-Moreno, Martin Rumbo, Francisco Hernández-Oliveros(A) Treg count and type of conditioning immunosuppression; non T-cell depleting (NTCD): basiliximab or rituximab, T-cell depleting (TCD): thymoglobulin or alemtuzumab. (B) Treg count and number of mismatches (ABDR). (C) Treg count and DSA presence/absence. Grey dots: patients without graft rejection; Black dots: patients with graft rejection. NTCD: Non T-cell depleting therapy; TCD: T-cell depleting therapy; DSA: Donor specific antibodies.
(PDF)
History
Usage metrics
Categories
Keywords
heightened immunological loadrejection rate surpassesgraft remained freegraft gene expressionacute cellular rejectionsmall bowel transplantationirreversible intestinal failureinflammatory mediators assessedtreg number comparedhistological findings resemblingsup >+receiving immunosuppression treatmentexperimental findings underscoregraft treg expansiongraft samples ).high treg frequency analyzedgraft rejectionhistological findingstreg frequencyintestinal transplantationgraft responsesvs inflammatory geneshigh cd8expansion withindiminished numberexperimental modelexperimental allogenicmucosa sampleshuman samplesblood samplesxlink ">significant reductionpotential involvementperipheral tolerancemrna upregulationmodulating hostkey playersincreased levelsimmunosuppressant treatmentfunctional graftsflow cytometryfacilitate bloodenhance longdiagnosed basedcurative optioncell chimerismanimals dividedallograft outcomes3 groups2 mg10 levels
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC